Please assess the completion status of the following clinical trial:

Trial Title: Tenofovir in Chronic Hepatitis B With Mild ALT Elevation

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* age between 25 to 70 years,~* serum HBsAg positivity for more than 6 months,~* positive or negative serum HBeAg,~* serum HBV DNA more than 2,000 IU/mL,~* highest serum ALT \> 1 fold of ULN, but \< 2 X ULN on at least two occasions (≧ 3 months apart) in the preceding one year,~Exclusion Criteria:~* co-infection with HIV, HCV, or HDV,~* previous exposure to HBV antiviral therapy for more than 12 weeks,~* presence of cirrhosis on histopathology,~* hepatic decompensation defined as serum bilirubin \> 2mg/dl and prolonged prothrombin time \> 3 seconds,~* concurrent malignant diseases including hepatocellular carcinoma,~* severe co-morbidity with life expectancy \< 1year,~* pregnant or lactating women,~* organ transplantation except cornea or hair transplant,~* suspected or confirmed chronic liver diseases from etiologies other than HBV (e.g. alcoholic hepatitis, Wilson disease, Hemochromatosis...etc),~* serum creatinine \>1.5mg/dL

- Gender: ALL
- Minimum Age: 25 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- TDF (Type: EXPERIMENTAL): tenofovir disoproxil fumarate (TDF) 300mg
- Placebo (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).